天天舔天天爽_视频日韩_成人网线_天天草草草_免费一级在线观看_色综合色综合色综合色综合

丹麥Symphogen
Symphogen是一家私營生物制藥公司， 70多個雇員，總部設在丹麥首都哥本哈根。

Symphogen is the leader in developing recombinant polyclonal antibodies (rpAb), a new class of biopharmaceuticals for the treatment or prophylaxis of serious human diseases.

Vision
Symphogen’s vision is to create superior antibody therapeutics by decoding the wisdom of nature.

Mission
With its pioneering antibody discovery and manufacturing technologies, Symphogen aims to create, develop, manufacture and commercialize target-specific recombinant antibodies that mirror the natural diversity and specificity of the human immune response. Symphogen is building a proprietary product pipeline within several core areas, including the replacement of plasma-derived immunoglobulins, infectious diseases, and cancer.

Symphogen's lead candidate, Sym001 (anti-RhD) for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) and the prevention of Hemolytic Disease in Newborns (HDN), became the first recombinant polyclonal antibody composition to enter clinical evaluation when Phase 1 trials were initiated in March of 2007.

Symphogen was founded in 2000 and is backed by a leading international venture capital investor syndicate.

Symphogen’s headquarters are located in Copenhagen, Denmark.